NervGen Pharma details CFO retirement and interim hire

NervGen Pharma Corp. reported a planned leadership change in its finance function.

Rhea-AI Filing Summary

NervGen Pharma Corp. reported a planned leadership change in its finance function. Chief Financial Officer and Secretary William J. Adams, who also serves as Principal Financial and Accounting Officer, has resigned due to his retirement, effective March 15, 2026. The company states that his resignation is not related to any disagreement with management or the board.

Adams will provide transitional services through June 15, 2026 and will receive one-third of his current base salary during this period, along with an extension of the expiration date of his vested stock awards under existing equity award agreements. The board has appointed Dr. Adam Rogers as interim Chief Financial Officer and Principal Financial and Accounting Officer, effective on the same date Adams’ resignation becomes effective. This report is also incorporated by reference into NervGen’s existing Form F-10 registration statement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did NervGen Pharma Corp. (NGEN) announce in this 6-K?

NervGen Pharma Corp. announced that William J. Adams will retire as Chief Financial Officer, Secretary, and Principal Financial and Accounting Officer effective March 15, 2026. The company has appointed Dr. Adam Rogers as interim Chief Financial Officer and Principal Financial and Accounting Officer starting on the same date.

Why is NervGen Pharma Corp. (NGEN) CFO William J. Adams resigning?

William J. Adams is resigning from his roles at NervGen Pharma Corp. due to his retirement. The company notes that his resignation is not the result of any disagreements with the company, its management, or its board of directors, framing this as an orderly leadership transition.

Will former CFO William J. Adams continue working with NervGen Pharma Corp. (NGEN) after his resignation?

Yes. After his resignation becomes effective on March 15, 2026, William J. Adams will provide transitional services to NervGen Pharma Corp. through June 15, 2026. During this period he will receive one-third of his current base salary and an extension of his vested stock award expiration dates.

Who will serve as interim CFO of NervGen Pharma Corp. (NGEN) after March 15, 2026?

The board of NervGen Pharma Corp. has appointed Dr. Adam Rogers as interim Chief Financial Officer and Principal Financial and Accounting Officer, effective March 15, 2026. His biography is incorporated by reference from a prior Form 6-K filed on February 10, 2026 with the Securities and Exchange Commission.

How is this NervGen Pharma Corp. (NGEN) 6-K related to its existing Form F-10 registration?

This report on Form 6-K, including its exhibits, is deemed incorporated by reference into NervGen Pharma Corp.’s Form F-10 registration statement (File No. 333-292197. It becomes part of that registration statement from the submission date, unless later documents or reports supersede the information it contains.

Does NervGen Pharma Corp. (NGEN) indicate any disagreement behind the CFO’s resignation?

NervGen Pharma Corp. specifically states that William J. Adams’ resignation was not due to any disagreements with the company, its management, or its board. This language is commonly used to signal an orderly transition rather than a dispute-driven departure from a key executive role.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:05 PM EST Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number: 001-43048

NERVGEN PHARMA CORP.

(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant’s name)

112-970 Burrard Street, Unit 1290
Vancouver, British Columbia, Canada V6Z 2R4
Telephone: (778) 731-1711
(Address and telephone number of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ¨   Form 40-F x

EXPLANATORY NOTE

Chief Financial Officer Resignation and Appointment

On February 12, 2026, NervGen Pharma Corp. (the “Company”) announced that William J. Adams tendered his resignation as the Chief Financial Officer and Secretary and Principal Financial and Accounting Officer of the Company, due to his retirement. Mr. Adams’ resignation is effective as of March 15, 2026 (the “Effective Date”). Mr. Adams’ resignation was not the result of any disagreements with the Company, its management or the Company’s Board of Directors (the “Board”).

Mr. Adams will be providing transitional services through June 15, 2026. In connection with these transitional services, Mr. Adams will receive one-third of his current base salary. Mr. Adams will also be entitled to receive an extension of the expiration date of his vested stock awards as set forth under his equity award agreements.

On February 12, 2026, the Board approved the appointment of Dr. Adam Rogers as the Company’s interim Chief Financial Officer and the Company’s Principal Financial and Accounting Officer, effective as of the Effective Date.

Dr. Rogers’ biography is incorporated by reference from the Company’s Report of Foreign Issuer on Form 6-K (File No. 001-43048) filed with the Securities and Exchange Commission on February 10, 2026.

INCORPORATION BY REFERENCE

This Report on Form 6-K, including the exhibits hereto, shall be deemed to be incorporated by reference into the registrant’s Registration Statement on Form F-10 (File No. 333-292197), to be a part thereof from the date on which this Report on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NERVGEN PHARMA CORP.
Date: February 13, 2026	By:	/s/ Adam Rogers
		Name: Adam Rogers
		Title: Chief Executive Officer